GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Collagen identification === CHPs can be used for visualizing many different types of collagen bands in SDS-PAGE gels. Collagen is denatured by heating in the presence of SDS prior to loading the gel. The collagen bands are visualized through CHP-collagen hybridization when the gels are stained by fluorescently-labeled CHPs.
=== France === A translated selection of articles are published with the French magazine Joypad. In 2017, La Financière de Loisirs licensed the title for France, starting with a 200 pages special issue about popular games that changed the gaming industry, as well AAA as indies.
== Interactions == When combined with antidepressants of the MAOI or SSRI class, very high parenteral doses of 5-HTP can cause acute serotonin syndrome in rats. It is unclear if such findings have clinical relevance, as most drugs will cause serious adverse events or death in rodents at very high doses. In humans, 5-HTP has never been clinically associated with serotonin syndrome – although a case report suggests 5-HTP can precipitate mania when added to an MAOI. When combined with carbidopa (as a treatment for symptoms of Parkinson's disease), 5-HTP causes nausea and vomiting; however, this can be alleviated via administration of granisetron. Cases of scleroderma-like illness have been reported in patients using carbidopa and 5-HTP. Oral 5-HTP results in an increase in urinary 5-HIAA, a serotonin metabolite, indicating that 5-HTP is peripherally metabolized to serotonin, which is then metabolized. This might cause false positive results in tests looking for carcinoid syndrome. Due to the conversion of 5-HTP into serotonin by the liver, there could be a risk of heart valve disease from serotonin's effect on the heart, as based on preclinical findings. However, 5-HTP has not been associated with cardiac toxicity in humans. It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements.
is large, which results in a larger plastic radius. This implies that the material can plastically deform, and, therefore, is tough. This estimate of the size of the plastic zone beyond the crack tip can then be used to more accurately analyze how a material will behave in the presence of a crack. The same process as described above for a single event loading also applies and to cyclic loading. If a crack is present in a specimen that undergoes cyclic loading, the specimen will plastically deform at the crack tip and delay the crack growth. In the event of an overload or excursion, this model changes slightly to accommodate the sudden increase in stress from that which the material previously experienced. At a sufficiently high load (overload), the crack grows out of the plastic zone that contained it and leaves behind the pocket of the original plastic deformation. Now, assuming that the overload stress is not sufficiently high as to completely fracture the specimen, the crack will undergo further plastic deformation around the new crack tip, enlarging the zone of residual plastic stresses. This process further toughens and prolongs the life of the material because the new plastic zone is larger than what it would be under the usual stress conditions. This allows the material to undergo more cycles of loading. This idea can be illustrated further by the graph of Aluminum with a center crack undergoing overloading events.
==== Muscle relaxants ==== In August 2025 the FDA approved cyclobenzaprine hydrochloride (produced under the brand name 'Tonmya') for use in fibromyalgia. Some trials had shown significant pain reduction although uncertainty remained on real world efficacy and scale of impact. The muscle relaxants cyclobenzaprine, carisoprodol with acetaminophen and caffeine, and tizanidine are sometimes used to treat fibromyalgia; however, as of 2015 they were not approved for this use in the United States.
Sources: en.wikipedia.org
Pumps further up the thin ascending limb, pump out from 400 mOsm into liquid at 600 mOsm, so again the difference is retained at 200 mOsm from the inside to the outside, while the concentration both inside and outside are gradually decreasing as the liquid flow advances. The liquid finally reaches a low concentration of 100 mOsm when leaving the thin ascending limb and passing through the thick one Distal convoluted tubule: Once leaving the loop of Henle the thick ascending limb can optionally reabsorb and re increase the concentration in the nephrons. Collecting duct: The collecting duct receives liquid between 100 mOsm if no re-absorption is done, to 300 or above if re-absorption was used. The collecting duct may continue raising the concentration if required, by gradually pumping out the same ions as the Distal convoluted tubule, using the same gradient as the ascending limbs in the loop of Henle, and reaching the same concentration. Ureter: The liquid urine leaves to the ureter. Same principle is used in hemodialysis within artificial kidney machines.
Marlowe (1988), creator of Castle; writer of Air Force One, End of Days, and Hollow Man Lawrence Trilling (1988), showrunner of Parenthood and Goliath Maiken Baird (1989), documentary film producer, Client 9: The Rise and Fall of Eliot Spitzer Sam Bisbee (1990), Emmy Award-winning producer and composer Gina Fattore (1990), producer and writer of Dawson's Creek, Gilmore Girls, Parenthood, creator of Dare Me Jeff Rake (1990), television producer, writer of Boston Legal and creator of Manifest and The Mysteries of Laura Dede Gardner (1990), Academy Award-winning producer of 12 Years a Slave; president of Plan B Entertainment Jenji Kohan (1991), television writer, producer, creator of Orange Is the New Black and Weeds Ari Gold (1992), filmmaker, director of Adventures of Power Elizabeth Craft (1993), producer, screenwriter, Fantasy Island, The 100, Lie to Me Ethan McSweeny (1993), former artistic director of the American Shakespeare Center, recipient of a 2018 Helen Hayes Award Brian Yorkey (1993), playwright, co-winner of the 2010 Pulitzer Prize for Drama for writing the musical Next to Normal Anna Winger (1993), screenwriter, creator of miniseries Deutschland 83, Deutschland 86, and Unorthodox Imara Jones (1994), political journalist and director Nicole Kassell (1994), director and producer of Watchmen, winner of the 2020 Directors Guild of America Award for Outstanding Directing – Drama Series Tim Carvell (1995), head writer of The Daily Show and executive producer of Last Week Tonight with John Oliver Josh Fox (1995), Academy Award-nominated documentary director, Gasland Adam Egypt Mortimer (1995), director of Daniel Isn't Real, Archenemy Henry Alex Rubin (1995), Academy Award-nominated director, Murderball Julius Sharpe (1995), television writer and showrunner of Making History and United We Fall Ramin Bahrani (1996), writer-director of Man Push Cart, Chop Shop and Fahrenheit 451, 2021 Academy Award for Best Adapted Screenplay nominee Moira Demos (1996), filmmaker who produced Netflix documentary Making a Murderer Yana Gorskaya (1996), Academy Award-nominated film editor, Spellbound Cetywa Powell (1996), director and fine art photographer Courtney Lilly (1997), television producer, showrunner of Black-ish, Grown-ish, Mixed-ish Nancy Schwartzman (1997), director, Roll Red Roll Beau Willimon (1999), creator and producer of House of Cards; writer of the play Farragut North Vikram Gandhi (2000), director, Kumaré, Barry, reporter for Vice Andrew Goldberg (2000), creator of Netflix series Big Mouth Ned Benson (2001), director, The Disappearance of Eleanor Rigby Dan Harris (2001), Saturn Award-winning screenwriter, X2, Superman Returns; director, Imaginary Heroes Andrew Neel (2001), filmmaker, director of King Kelly, Goat Anna Boden (2002), co-writer of Half Nelson and director of Sugar, Captain Marvel Tze Chun (2002), award-winning director, Children of Invention Lang Fisher (2002), co-creator of Never Have I Ever, writer of 30 Rock and Brooklyn Nine-Nine, Peabody Award winner in 2008 Susanna Fogel (2002), Emmy Award and BAFTA Award-nominated director Will Graham (2002), creator of the Onion News Network, showrunner of Mozart in the Jungle, Peabody Award winner in 2008 Ashley Lyle (2002), screenwriter, showrunner of Yellowjackets Justin Marks (2002), screenwriter, The Jungle Book, Counterpart Katori Hall (2003), playwright, The Mountaintop, winner of the 2021 Pulitzer Prize for Drama Raamla Mohamed (2003), Emmy Award-nominated screenwriter, Little Fires Everywhere Graham Moore (2003), winner of the 2015 Academy Award for Best Adapted Screenplay for his screenplay of The Imitation Game Lucia Aniello (2004), director of Rough Night and Time Traveling Bong Gabe Liedman (2004), creator of Q-Force, writer of Brooklyn Nine-Nine, PEN15, Inside Amy Schumer and Kroll Show Zhang Mo (2005), Chinese director, daughter of Zhang Yimou Laura Goode (2006), author, columnist, and producer of Farah Goes Bang Matt Kaplan (2006), producer of young adult films, To All the Boys franchise Meera Menon (2006), Indian-American director, Equity Lilly Burns (2009), television producer, co-founder of Jax Media and president of Imagine Entertainment Eli Bush (2009), film and theatre producer and winner of the Golden Globe Award in 2018 for Lady Bird Jason Fuchs (2009), actor and screenwriter, Pan, Ice Age: Continental Drift Jessica Kingdon (2009), Academy Award-nominated Chinese-American documentary director Nuotama Bodomo (2010), Ghanaian filmmaker and co-writer of sketch comedy Random Acts of Flyness on HBO Sabaah Folayan (2013), director of documentary Whose Streets?
=== Irrigation === Proper cleansing of a wound is critical in preventing infection and promoting healing of any wound. Irrigation is defined as constant flow of a solution over the surface of a wound. The goal of irrigation is not only to remove debris and potential contaminants from a wound, but also to assist in visual inspection of a wound and hydrate the wound. Irrigation is typically achieved with either a bulb or syringe and needle/catheter. The preferred solution for irrigation is normal saline which is readily accessible in the emergency department, although recent studies have shown no difference in emergency department infection rates when comparing normal saline to potable tap water. Irrigation can also be achieved with a diluted 1% povidone iodine solution, but studies have again shown no difference in infection rates when compared to normal saline. Irrigation with antiseptic solutions, such as non-diluted povidone iodine, chlorhexidine, and hydrogen peroxide is not preferred since these solutions are toxic to tissue and inhibit wound healing. The exact volume of irrigation used will vary depending on the appearance of the wound, although some sources have reported 50–100 mL of irrigation per 1 cm of wound length as a guideline.
Spinneys, which holds a 50-year lease with a 382,900 ft² cold storage distribution centre BRF (Brasil Foods), which operates a 1.6 million sq plant producing meat products and bread-based foods under the Sadia brand. Emirates Calcium Carbonate Factory, established under a 50-year agreement to supply products for oilfield industries Palletco, a manufacturing facility under a 50-year lease agreement. Apex Engineering Industries, an AED 90 million manufacturing facility for oil, gas and defence. Abundance Solar Panel Industries, an AED 55 million solar production plant. Global logistics companies, including DHL Global Forwarding and DSV, which provide logistics and supply chain services. Azizi Developments, which signed a 50-year land lease agreement to build 12 factories with an investment of AED 1 billion. Jiangsu Overseas Cooperation Investment Co. Ltd (JOCIC), established in 2017 to manage the China-UAE Industrial Capacity Cooperation Demonstration Zone. Built-to-suit
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.